Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine

Inclusion Criteria

• •Male or female subjects aged between 18 and 45 years, inclusive.
• •Subjects of body mass index (BMI) between 19 and 30 kg/m2, inclusive.
• •Subjects who were healthy as determined by pre-study medical history, physical examination, vital signs, neurological examination, and 12-lead ECG.
• •Subjects who had clinical laboratory tests clinically acceptable at screening and admission.
• •Subjects who had negative tests for HBsAg, anti-HCV Ab and HIV-1 and HIV-2 Ab at screening.
• •Subjects who were negative for drugs of abuse and alcohol at screening and admission.
• •Subjects who were non-smokers or who smoke \< 10 cigarettes or equivalent per day.
• •Subjects who are able and willing to give written informed consent.
• •(If female) She was not of childbearing potential by reason of surgery or, if of childbearing potential, she used one of the following methods of contraception: double barrier, intrauterine device or abstinence.
• •(If female) She had a negative pregnancy test at screening and admission to Phase A.
• •Subjects who had a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders.
• •Subjects who had a clinically relevant surgical history.
• •Subjects who had a clinically relevant family history.
• •Subjects who had a history of relevant atopy.
• •Subjects who had a history of relevant drug hypersensitivity (especially carbamazepine or oxcarbazepine).
• •Subjects who had a history of alcoholism or drug abuse.
• •Subjects who consumed more than 14 units of alcohol a week.
• •Subjects who had a significant infection or known inflammatory process on screening or admission.